Key result
Anti-OxLDL-USPIO nanoparticles produce greater MRI signal loss in carotid atherosclerotic lesions versus controls.
Why the study?
OxLDL plays a key role in atherosclerotic plaque formation and rupture, but direct in vivo detection of OxLDL in lesions remains challenging.
Does anti-OxLDL-USPIO improve in vivo MRI detection of atherosclerotic lesions in ApoE-deficient mice?
Does anti-OxLDL-USPIO improve in vivo MRI detection of atherosclerotic lesions in ApoE-deficient mice?
Anti-OxLDL-USPIO nanoparticles enable direct in vivo MRI detection of OxLDL in atherosclerotic lesions within 24 hours, offering a potential strategy for evaluating atherosclerotic plaques.
Answers are grounded in this paper and cite their sources.
Supports targeted OxLDL MRI in murine atherosclerosis; leaves open human translation and safety.
Atherosclerotic disease is a leading cause of morbidity and mortality in developed countries, and oxidized LDL (OxLDL) plays a key role in the formation, rupture, and subsequent thrombus formation in atherosclerotic plaques. In the current study, anti-mouse OxLDL polyclonal antibody and nonspecific IgG antibody were conjugated to polyethylene glycol-coated ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, and a carotid perivascular collar model in apolipoprotein E-deficient mice was imaged at 7.0 Tesla MRI before contrast administration and at 8 h and 24 h after injection of 30 mg Fe/kg. The results showed MRI signal loss in the carotid atherosclerotic lesions after administration of targeted anti-OxLDL-USPIO at 8 h and 24 h, which is consistent with the presence of the nanoparticles in the lesions. Immunohistochemistry confirmed the colocalization of the OxLDL/macrophages and iron oxide nanoparticles. The nonspecific IgG-USPIO, unconjugated USPIO nanoparticles, and competitive inhibition groups had limited signal changes (p < 0.05). This report shows that anti-OxLDL-USPIO nanoparticles can be used to directly detect OxLDL and image atherosclerotic lesions within 24 h of nanoparticle administration and suggests a strategy for the therapeutic evaluation of atherosclerotic plaques in vivo.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2012) studied Atherosclerotic lesions. Anti-OxLDL-USPIO nanoparticles vs. Nonspecific IgG-USPIO, unconjugated USPIO nanoparticles, and competitive inhibition was evaluated on MRI signal loss in carotid atherosclerotic lesions (p=< 0.05). Anti-OxLDL-USPIO nanoparticles produced significant MRI signal loss in carotid atherosclerotic lesions at 8 and 24 hours compared to nonspecific and unconjugated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: